# US 2013/0096195 A1 · Therapeutic treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0096195 A1
- Document ID: US20130096195A1
- Status: Published application
- Kind: A1
- Application number: 13/709,833
- Filed: 2012-12-10
- Published: 2013-04-18
- Earliest claimed: 2003-07-15
- Inventors: Jallal Messadek
- Web page: https://patentgrep.com/patent/US20130096195A1

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/10: for impotence
- A61P 27/02: Ophthalmic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention describes the use of betaine alone for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.

## Claims

### Claim 1

A method for increasing the initial claudication distance in a patient suffering from peripheral arterial diseases and/or intermittent claudication, said method comprising administering to said patient, as a therapeutically active agent for increasing the initial walking distance, a composition comprising as a single active ingredient a therapeutically effective amount of at least one therapeutically active compound selected from the group consisting of betaine of formula (CH3)3 N+ (CH2)COO−, pharmaceutically active salts thereof and mixtures thereof, so as to increase said initial claudication distance.

### Claim 2 (depends on 1)

The method of claim 1, in which the therapeutically effective amount of at least one therapeutically active compound selected from the group consisting of betaine of the formula (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient for at least 4 weeks.

### Claim 3 (depends on 2)

The method of claim 2, in which said patient has improvement of said initial claudication distance by at least 25% after 4 weeks.

### Claim 4 (depends on 1)

The method of claim 1, in which the therapeutically effective amount of at least one therapeutically active compound selected from the group consisting of betaine of the formula (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is orally administered to said patient.

### Claim 5 (depends on 1)

The method of claim 1, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is administered to said patient with a dosage form selected from the group consisting of the once daily administration forms and the twice daily administration forms.

### Claim 6 (depends on 1)

The method of claim 1, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is administered to said patient with an extended release dosage form.

### Claim 7 (depends on 1)

The method of claim 1, in which at least 1000 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.

### Claim 8 (depends on 1)

The method of claim 1, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

### Claim 9 (depends on 1)

The method of claim 1, in which from 250 mg to 3000 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2) COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

### Claim 10 (depends on 1)

The method of claim 1, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form, while at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.

### Claim 11 (depends on 1)

The method of claim 1, wherein the single active ingredient in said composition is glycine betaine.

### Claim 12

A method for treating a patient suffering of peripheral arterial diseases and/or intermittent claudication, said method comprising administering to said patient, as a therapeutically active agent, a composition comprising as a single active ingredient a therapeutically effective amount of at least one therapeutically active compound selected from the group consisting of betaine of formula (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof.

### Claim 13 (depends on 12)

The method of claim 12, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is orally administered to said patient.

### Claim 14 (depends on 12)

The method of claim 12, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is a unit dose of glycine betaine of at least 500 mg in immediate release dosage form.

### Claim 15 (depends on 12)

The method of claim 12, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is administered to said patient with a dosage form selected from the group consisting of the once daily administration forms and the twice daily administration forms.

### Claim 16 (depends on 12)

The method of claim 12, in which the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is administered to said patient as an extended release dosage form.

### Claim 17 (depends on 12)

The method of claim 12, in which at least 1000 mg of the therapeutically active compound selected from the group consisting of (CH3)3N+(CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.

### Claim 18 (depends on 12)

The method of claim 12, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3 N+ (CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

### Claim 19 (depends on 12)

The method of claim 12, in which from 250 mg to 3000 mg of the therapeutically active compound selected from the group consisting of (CH3)3 N+ (CH2) COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

### Claim 20 (depends on 12)

The method of claim 12, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3 N+ (CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form, while at least 250 mg of the therapeutically active compound selected from the group consisting of (CH3)3 N+ (CH2)COO−, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.
